Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | CBX7 | O95931 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4122385 | 0.92 | HCRTR1 (0.38) | PTGS1HCRTR1HCRTR2CBX7ALDH1A1 | |
| SCHEMBL13775799 | 0.89 | ALDH1A1 (0.40) | HCRTR1HCRTR2ALDH1A1KDM4ENPC1 | |
| SCHEMBL4121992 | 0.79 | NR1I2 (0.41) | CBX7ALDH1A1KDM4ENPC1LMNA | |
| SCHEMBL4111361 | 0.78 | HCRTR1 (0.38) | HCRTR1HCRTR2ALDH1A1KDM4ENPC1 | |
| SCHEMBL13775802 | 0.77 | KMT2A (0.40) | HCRTR1HCRTR2ALDH1A1KDM4ENPC1 | |
| SCHEMBL4125269 | 0.74 | NR1I2 (0.39) | KMT2A | |
| SCHEMBL4118375 | 0.73 | HCRTR1 (0.37) | HCRTR1HCRTR2ALDH1A1KDM4ENPC1 | |
| SCHEMBL4110971 | 0.73 | KMT2A (0.33) | HCRTR1HCRTR2ALDH1A1KDM4ENPC1 | |
| SCHEMBL4122687 | 0.70 | L3MBTL1 (0.44) | ALDH1A1KDM4ENPC1LMNARAB9A | |
| SCHEMBL4120170 | 0.70 | RORB (0.39) | ALDH1A1KDM4ENPC1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | FDFT1, COASY, HMGCR | PTGS1 254/4885HCRTR1 1006/4885HCRTR2 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.